HomeCompareORPH vs KMB

ORPH vs KMB: Dividend Comparison 2026

ORPH yields 229.89% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPH wins by $273.52M in total portfolio value
10 years
ORPH
ORPH
● Live price
229.89%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$273.56M
Annual income
$147,417,011.12
Full ORPH calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — ORPH vs KMB

📍 ORPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPH + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORPH pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPH
Annual income on $10K today (after 15% tax)
$19,540.23/yr
After 10yr DRIP, annual income (after tax)
$125,304,459.45/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, ORPH beats the other by $125,300,029.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPH + KMB for your $10,000?

ORPH: 50%KMB: 50%
100% KMB50/50100% ORPH
Portfolio after 10yr
$136.80M
Annual income
$73,711,111.22/yr
Blended yield
53.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ORPH
No analyst data
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPH buys
0
KMB buys
0
No recent congressional trades found for ORPH or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHKMB
Forward yield229.89%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$273.56M$45.9K
Annual income after 10y$147,417,011.12$5,211.33
Total dividends collected$259.68M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ORPH vs KMB ($10,000, DRIP)

YearORPH PortfolioORPH Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$33,689$22,988.51$11,314$613.68+$22.4KORPH
2$108,425$72,378.36$12,865$759.19+$95.6KORPH
3$333,722$217,707.23$14,709$943.96+$319.0KORPH
4$983,328$626,245.04$16,919$1,180.17+$966.4KORPH
5$2,776,703$1,724,542.37$19,588$1,484.33+$2.76MORPH
6$7,522,223$4,551,151.29$22,838$1,879.06+$7.50MORPH
7$19,571,480$11,522,701.34$26,832$2,395.60+$19.54MORPH
8$48,960,184$28,018,699.69$31,788$3,077.63+$48.93MORPH
9$117,893,771$65,506,373.98$38,000$3,986.82+$117.86MORPH
10$273,563,346$147,417,011.12$45,872$5,211.33+$273.52MORPH

ORPH vs KMB: Complete Analysis 2026

ORPHStock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPH Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ORPH vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPH vs SCHDORPH vs JEPIORPH vs OORPH vs KOORPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.